Show simple item record

dc.contributor.authorBudiasih, Kun Sri
dc.contributor.authorPertiwi, Kartika Ratna
dc.date.accessioned2015-10-30T05:59:23Z
dc.date.available2015-10-30T05:59:23Z
dc.date.issued2015-10-30
dc.identifier.citation[1] WHO, Report of a WHO Consultation World Health Organization, Department of Non communicable Disease Surveillance, 1999, Geneva. [2] A Pranoto, A Sutjahjo, A Tjokroprawiro, S Murtiwi, S Wibisono, LPPM, 2011, Universitas Airlangga, Surabaya. [3] H Dureja, D Kaushik, V Kumar, Development in Nutraceuticals, Indian Journal Of Pharmacology, 35, 363-372 [4] S.P. Macharla, V. Goli, S.R. Sattla, J. Chem. Pharm. Res., 2012, 4(3):1519-1522 [5] K. P. S. Kumar, D. Bhowmik, Chiranjib, Biswajit, and P. Tiwari, Screening of Madhuca Indica for Antidiabetic Activity in Streptozotocin and Streptozotocin-Nicotinammida Induced Diabetic Rats , J. Chem. Pharm. Res., 2010, 2(1): 283-291 [6] Malone, M Rosette, Metals In Medicine, Bioinorganic Chemistry: A Short Course., John Wiley & Sons, Inc., 2002, ISBN: 0-471-15976-X. [7] K.Hariprasath, B. Deepthi, I. Sudheer Babu, P. Venkatesh, S. Sharfudeen, V. Soumya, Metal Complexes in Drug Research - A Review, J. Chem. Pharm. Res., 2010, 2(4):496-499. [8] Z Krejpcio, Essentiality of Chromium for Human Nutrition and Health , Pol.J, Environ. Studies, 2001, 10 (6) 399-404. [9] JB Vincent, (ed), The Nutritional Biochemistry of Chromium(III),Elsevier,New York, 2007 : 139-151. [10] RA Anderson., Chromium and the Prevention and Control of Diabetes, Diabetes & Metabolism, 2007,vol.26, p. 22-27. [11] D Boghchi, SJ Stohs, BW Downs, Cytotoxicity and Oxidative Mechanism of Different Forms of Chromium Toxicology, 2002, No. 180 (1), 5-22. [12] DD Hepburn, JM Burney, K Woski, JB Vincent, The Nutritional Supplement Chromium Picolinate Generates Oxidative DNA Damage and Peroxidized Lipids In Vivo Polyhedron, 2003, 22 (3):.455-463 . [13] AA Nedim, BZ Karan, R Öner., C Ünaleroglu, C Öner, Effects of Neutral, Cationic, and Anionic Chromium Ascorbate Complexes on Isolated Human Mitochondrial and Genomic DNA, J. of Biochem. Mol. Bio., 2003, 36 (4), 403-408. [14] XPYang, P Kamalakannan, C Allyn. MNA Ontkoa, XF Cindy, J Rena., N Sreejayan, A Newly Synthetic Chromium Complex Chromium(Phenylalanine)3 Improves Insulin Responsiveness and Reduces Whole Body Glucose Tolerance FEBS Letters , 2005 :579, 1458–1464. [15] E.Ochiai, Bioinorganic Chemistry, John Willey & Sons, New York. 2008, p.235. [16] KS Karthikeyan, P Nagababu, K Sastry, Sivarama, S Satyanarayana, Current Trends in Biotechnology and Pharmacy, 2010, 4(4),908-916 [17] KS Karthikeyan., World Congress of Biotechnology, 2011,NICC, Hyderabad, India. [18] K.S. Budiasih, C.Anwar, S.J.Santosa, H.Ismail, Synthesis and Characterization of Chromium (III) Complexes with L-Glutamic Acid, Glycine and L- CysteineWorld Academy of Science Engineering & Technology (Waset) Journal, 2013: 78, pp 1095-1909. [19] EU Etuk, 2010, Animals Models for Studying Diabetes Mellitus, Agric. Bio. J. of. N. Am., 2010:1 (2), 130-134. [20] A Shirwaikar, K Rajendran, CD Kumar., R Bodla, Antidiabetic Actiivity of Aqueous Leaf Extract of Anona Squamosa in Streptozotocin-nicotinamide type 2 Diabetic Rats, J. Of. Etnopharmacology : 2004, 91 : 171-175. [21] Flores, C.R; Puga, M.P.; Wrobel, K.; Garay Sevilla, M.E.; Wrobel, K. 2011, Trace Elements Status in Diabetes Mellitus Type 2: Possible Role of the Interaction Between Molybdenum and Copper in the Progress of Typical Complications, Diabetes Res Clin Pract. Mar; 91(3),333-41. [22] PG Astiyandani, PG., AW Angga Permana, PD.Vedayanti, ID Cok. MP Larayanthi, Windasari dan I.A.I Wahyuniari, Uji Klinis In Vivo Pengaruh Konsumsi Daluman (Cycllea Barbata) Terhadap Penurunan Kadar Gula Darah pada Tikus Wistar Jantan Dengan Diabetes Mellitus Tipe 2, IPTEKMA, 2010, Vol.2 No.1, 01-04. [23] M Sharma, M. Siddique, M.W.., Shamim, A.M., Gyanesh, ., and K.K. Pillai, Evaluation of Antidiabetic and Antioxidant Effects of Seabuckthorn (Hippophaerhamnoides L.) in Streptozotocin-Nicotinamide Induced Diabetic Rats, The Open Conference Proceedings Journal, 2011, 2, 53-58. [24] MY Selcuk, B Aygen, A Dogukan, Z Tuzcu, F Akdemir, J Komorowski, M Atalay, K Sahin, Chromium Picolinate and Chromium Histidinate Protects Against Renal Dysfinction by Modulation of NF-B pathway in high-fat diet fed and Streptozotocin-induced Diabetic Rats , Nut. & Met., 2012, 9:30. [25] A, Shirwaikar, A., Rajendran K., Kumar C.D., Bodla R., 2004, Antidiabetic Actiivity of Aqueous Leaf Extract of Anona Squamosa in Streptozotocin- nicotinamide type 2 Diabetic Rats, J. Of. Etnopharm. : 91, 171-175. [26] S Ramachandran, A Rajasekaran, KT Kumar. Antidiabetic, Antihyperlipidemic and Antioxidant Potential of Methanol Extract of Tectona Grandis Flowers in Streptozotocin Induced Diabetic Rats, App J. Of Trop. Med : 2011, 624-631. [27] P Murugan, L Pari, Life Sciences, 2006: 79, 1720-1728. [28] R Yanardag, TB Demirci, B Ulkuseven, S Bolkent, S Tunali, S Bolkent, Synthesis, Characterization and Antidiabetic properties of N1-2,4- dihydroxybenzylidene-N4-2-dihydroxybenzylidene- S-methylthiosemicarbazidato-oxovanadium(IV), Euro.J.Med.Chem, 2009, 44: 818-826. [29] PC Are, RR Adidala, G Puchchakayala, Hypoglycemic and Antidiabetic Activity of Glocidion velutinum on streptozotocin- nicotinamide Induced Type2 Diabetic Rats, Eur. J. Biol.Sci, 2011, 3(4); 126-130. [30] SS Ibrahim, SF Rizk, Nicotinamid: A cytoprotectant against streptozotocin-induced diabetic damage in wistar rat brains, Afr.J. Biochem.Res, 2008, 2 (8), pp.174-180.in_ID
dc.identifier.issn9-772476-969006
dc.identifier.urihttp://hdl.handle.net/11617/6197
dc.description.abstractThe chromium (III)-amino acid complex based hypoglicemic agent was investigated on pre-clinical study by the response of the blood glucoce level. This study was conducted on nicotinamide-streptozotocin induced diabetic Wistar rats. The rats were divided into 7 groups each consist of 4 animals. Three groups are control (+) with chromium picolinate (CrPic), control (-) diabetic group (DM) and control non diabetic (non DM). Furthermore, three groups were examined on the effect of Cr-AA [Cr(μ-OH)(glu)(OH)2]2·6H2O] (glu= glutamic) at dose (50, 150 and 300 μg/day). In addition, the last group was studied on the effect of control group by glibenclamide. The blood glucose levels were measured before and after treatment. The results show that supplementation of Cr(III)-complex in 8 weeks decreased the blood glucose level in range 46.446 – 79.593 %.in_ID
dc.language.isoenin_ID
dc.publisherUniversitas Muhammadiyah Surakartain_ID
dc.subjecthypoglicemicin_ID
dc.subjectchromium (III)in_ID
dc.subjectamino acidin_ID
dc.subjectcomplexesin_ID
dc.subjectnicotinamide-streptozotocinin_ID
dc.subjectdiabetic ratsin_ID
dc.titlePre Clinical Study of Cr(III)-based Hypoglicemic Supplementin–Type 2 Diabetic Ratsin_ID
dc.typeArticlein_ID


Files in this item

Thumbnail

This item appears in the following Collection(s)

  • ICB-PHARMA II
    Current Breakthrough in Pharmacy Materials and Analyses

Show simple item record